莫西沙星联合卷曲霉素治疗耐多药肺结核的临床效果

Clinical Effect of Moxifloxacin Combined with Capreomycin in the Treatmnet of Multi-Drug Resistant Tuberculosis

目的 探讨莫西沙星联合卷曲霉素治疗耐多药肺结核的临床效果。方法 选取我院收治的80例耐多药肺结核患者,随机将其分为两组各40例。观察组采用莫西沙星联合卷曲霉素治疗,对照组采用常规治疗。比较两组的临床疗效,腺苷脱氨酶、C反应蛋白水平及并发症情况。结果 观察组治疗总有效率为95.0%,明显高于对照组的40.0%(P <0.05)。治疗后,观察组腺苷脱氨酶、 C反应蛋白水平明显低于对照组(P <0.05)。观察组的并发症发生率为7.50%,明显低于对照组的27.50%(P <0.05)。结论 莫西沙星联合卷曲霉素治疗耐多药肺结核的疗效显著,可有效降低炎性因子水平和并发症发生率,值得临床推广应用。

Objective To explore the clinical effect of moxifloxacin combined with capreomycin in the treatment of multi-drug resistant tuberculosis.Methods 80 patients with multi-drug resistant tuberculosis admitted to our hospital were selected and randomly divided into two groups,with 40 cases in each group.The observation group was treated with moxifloxacin combined with capreomycin,and the control group was given routine treatment.The clinical efficacy,levels of adenosine deaminase and C-reactive protein and complications were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.0%,significantly higher than 40.0% in the control group(P <0.05).After treatment,the levels of adenosine deaminase and C-reactive protein in the observation group were significantly lower than those in the control group(P <0.05).The incidence of complications in the observation group was 7.50%,significantly lower than 27.50% in the control group(P <0.05).Conclusions Moxifloxacin combined with capreomycin has significant efficacy in the treatment of multi-drug resistant tuberculosis,and can effectively reduce the levels of inflammatory factors and the incidence of complications,which is worthy of clinical promotion and application.